Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1982 Jan;79(2):626–629. doi: 10.1073/pnas.79.2.626

A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

A Trouet, M Masquelier, R Baurain, D Deprez-De Campeneere
PMCID: PMC345799  PMID: 6952214

Abstract

Daunorubicin (DNR) has been conjugated to succinylated serum albumin by an amide bond joining the amino group of the drug and a carboxyl side chain of the protein either directly or with the intercalation of a peptide spacer arm varying from one to four amino acids. During in vitro incubation with lysosomal hydrolases, intact DNR could be released extensively only from conjugates prepared with a tri- or tetrapeptide spacer arm. These latter conjugates remained very stable in the presence of serum. When tested in vivo against the intraperitoneal form of L1210 leukemia, the conjugates in which DNR was linked to serum albumin directly or via one amino acid were completely inactive but the conjugate with a dipeptide spacer arm was not more active than free DNR. In parallel with the in vitro studies, the best therapeutic results were obtained with the conjugates formed with tri- and tetrapeptidic spacer arms; they were much more active than DNR, inducing a high percentage of long-term survivors. Thus, use of a tri- or tetrapeptide spacer arm is essential to obtain DNR-protein conjugates that remain stable in serum and from which DNR can be released through the action of lysosomal hydrolases. The in vivo results suggest, moreover, that these conjugates are endocytosed by L1210 cells and that DNR is released intracellularly after digestion by lysosomal enzymes. This conjugation method can be applied to other drugs possessing a free amino group and to various potential carriers, such as antibodies, polypeptide hormones, and glycoproteins, that have amino or carboxyl side chains.

Full text

PDF
626

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baurain R., Deprez-De Campeneere D., Trouet A. Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chromatography: plasma levels in DBA2 mice. Cancer Chemother Pharmacol. 1979;2(1):11–14. doi: 10.1007/BF00253098. [DOI] [PubMed] [Google Scholar]
  2. Deprez-de Campeneere D., Trouet A. DNA--anthracycline complexes. I. Toxicity in mice and chemotherapeutic activity against L1210 leukemia of daunorubicin--DNA and adriamycin--DNA. Eur J Cancer. 1980 Aug;16(8):981–986. doi: 10.1016/0014-2964(80)90243-1. [DOI] [PubMed] [Google Scholar]
  3. Ghose T., Blair A. H. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects. J Natl Cancer Inst. 1978 Sep;61(3):657–676. [PubMed] [Google Scholar]
  4. Gregoriadis G., Neerunjun E. D. Homing of liposomes to target cells. Biochem Biophys Res Commun. 1975 Jul 22;65(2):537–544. doi: 10.1016/s0006-291x(75)80180-x. [DOI] [PubMed] [Google Scholar]
  5. Habeeb A. F. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem. 1966 Mar;14(3):328–336. doi: 10.1016/0003-2697(66)90275-2. [DOI] [PubMed] [Google Scholar]
  6. Hurwitz E., Levy R., Maron R., Wilchek M., Arnon R., Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res. 1975 May;35(5):1175–1181. [PubMed] [Google Scholar]
  7. Hurwitz E., Maron R., Arnon R., Wilchek M., Sela M. Daunomycin--immunoglobulin conjugates, uptake and activity in vitro. Eur J Cancer. 1978 Nov;14(11):1213–1220. doi: 10.1016/0014-2964(78)90227-x. [DOI] [PubMed] [Google Scholar]
  8. Kaneko Y. Thyrotropin-daunomycin conjugate shows receptors-mediated cytotoxicity in cultured thyroid cells. Horm Metab Res. 1981 Feb;13(2):110–114. doi: 10.1055/s-2007-1019187. [DOI] [PubMed] [Google Scholar]
  9. Kitao T., Hattori K. Concanavalin A as a carrier of daunomycin. Nature. 1977 Jan 6;265(5589):81–82. doi: 10.1038/265081a0. [DOI] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. Masquelier M., Baurain R., Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J Med Chem. 1980 Nov;23(11):1166–1170. doi: 10.1021/jm00185a003. [DOI] [PubMed] [Google Scholar]
  12. Monsigny M., Kieda C., Roche A. C., Delmotte F. Preparation and biological properties of a covalent antitumor drug--arm---carrier (DAC conjugate). FEBS Lett. 1980 Sep 22;119(1):181–186. doi: 10.1016/0014-5793(80)81026-x. [DOI] [PubMed] [Google Scholar]
  13. Niederwieser A. Adsorption of neutral polystyrene resin. A simple method for extraction of 2,4-dinitrophenyl derivatives from aqueous solution and for decoloration of protein hydrolysates. J Chromatogr. 1971 Jan 20;54(2):215–223. doi: 10.1016/s0021-9673(01)80267-3. [DOI] [PubMed] [Google Scholar]
  14. Peterson C., Trouet A. Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts. Cancer Res. 1978 Dec;38(12):4645–4649. [PubMed] [Google Scholar]
  15. Rustum Y. M., Dave C., Mayhew E., Papahadjopoulos D. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. Cancer Res. 1979 Apr;39(4):1390–1395. [PubMed] [Google Scholar]
  16. Ryser H. J., Shen W. C. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3867–3870. doi: 10.1073/pnas.75.8.3867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Trouet A. U., Pirson P., Steiger R., Masquelier M., Baurain R., Gillet J. Development of new derivatives of primaquine by association with lysosomotropic carriers. Bull World Health Organ. 1981;59(3):449–458. [PMC free article] [PubMed] [Google Scholar]
  18. Trouet A., Deprez-de Campeneere D., De Duve C. Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nat New Biol. 1972 Sep 27;239(91):110–112. doi: 10.1038/newbio239110a0. [DOI] [PubMed] [Google Scholar]
  19. Trouet A. Isolation of modified liver lysosomes. Methods Enzymol. 1974;31:323–329. doi: 10.1016/0076-6879(74)31034-8. [DOI] [PubMed] [Google Scholar]
  20. Trouet A. Perspectives in cancer research. Increased selectivity of drugs by linking to carriers. Eur J Cancer. 1978 Feb;14(2):105–111. doi: 10.1016/0014-2964(78)90167-6. [DOI] [PubMed] [Google Scholar]
  21. Varga J. M., Asato N., Lande S., Lerner A. B. Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells. Nature. 1977 May 5;267(5606):56–58. doi: 10.1038/267056a0. [DOI] [PubMed] [Google Scholar]
  22. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974 Sep 15;23(18):2495–2531. doi: 10.1016/0006-2952(74)90174-9. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES